Biological agents, mainly monoclonal antibodies or fusion proteins, which intervene with specific molecules of the body’s immune system, are used to treat immune-mediated inflammatory diseases and tumors. The main biologics that can be used in psoriasis are cytokine TNF-α, IL-12/23/17A inhibitors. 1. Tumor necrosis factor alpha (TNF-α) inhibitors are mainly infliximab, etanercept, adalimumab. 2. Interleukin 12/23 (IL-12/23) inhibitors are mainly ustekinumab. 3. Interleukin 23 (IL-23) inhibitors are mainly gusecimab. 4. Interleukin 17A (IL-17A) inhibitors are mainly ezekizumab and stuclizumab. Biologics are mainly used in patients with moderate-to-severe psoriasis who are refractory to or unable to tolerate conventional treatment. Contraindications include allergy to the protein components of the biologics, tuberculosis or other active infections, and moderate-to-severe heart failure. If you have psoriasis, please go to the hospital as soon as possible, the doctor to develop an individualized plan, and follow the doctor’s instructions for medication, so as not to delay the condition.